AbbVie's Ongoing Vitiligo Study in China: Implications for Market Performance and Healthcare Strategies

AbbVie has announced an update on its ongoing clinical study, Elevate Your Investing Strategy, focused on vitiligo in China. The study aims to evaluate treatment patterns, healthcare resource utilization, and the burden of non-segmental vitiligo (NSV) among patients. As an observational, cross-sectional study, it will analyze data from a specific group of patients at a single point in time without any intervention. The study began on July 1, 2025, and is ongoing. Further details are available on the ClinicalTrials portal.